Design Therapeutics, Inc. (NASDAQ:DSGN) Expected to Post Earnings of -$0.14 Per Share

Wall Street analysts expect Design Therapeutics, Inc. (NASDAQ:DSGN) to report earnings per share (EPS) of ($0.14) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Design Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.13). The company is scheduled to report its next quarterly earnings results on Monday, November 8th.

According to Zacks, analysts expect that Design Therapeutics will report full year earnings of ($0.71) per share for the current year, with EPS estimates ranging from ($0.72) to ($0.69). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.94) per share, with EPS estimates ranging from ($1.02) to ($0.85). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow Design Therapeutics.

Design Therapeutics (NASDAQ:DSGN) last posted its earnings results on Monday, August 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.04.

Separately, Zacks Investment Research raised Design Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, July 12th.

In other news, Director Arsani William purchased 40,000 shares of Design Therapeutics stock in a transaction that occurred on Tuesday, August 31st. The shares were bought at an average cost of $15.45 per share, with a total value of $618,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

A number of hedge funds have recently modified their holdings of DSGN. Price T Rowe Associates Inc. MD boosted its holdings in Design Therapeutics by 1.0% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,448,968 shares of the company’s stock worth $28,168,000 after acquiring an additional 13,714 shares in the last quarter. Citadel Advisors LLC boosted its holdings in Design Therapeutics by 1.2% in the second quarter. Citadel Advisors LLC now owns 2,566,148 shares of the company’s stock worth $49,941,000 after acquiring an additional 31,445 shares in the last quarter. California State Teachers Retirement System bought a new stake in Design Therapeutics in the second quarter worth $370,000. Credit Suisse AG boosted its holdings in Design Therapeutics by 291.0% in the second quarter. Credit Suisse AG now owns 240,158 shares of the company’s stock worth $4,777,000 after acquiring an additional 178,730 shares in the last quarter. Finally, Pinz Capital Management LP bought a new stake in Design Therapeutics in the second quarter worth $86,000. 49.70% of the stock is currently owned by institutional investors.

DSGN opened at $16.17 on Friday. Design Therapeutics has a 52-week low of $13.93 and a 52-week high of $50.50. The company’s 50 day simple moving average is $16.79.

About Design Therapeutics

Design Therapeutics, Inc develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy.

See Also: Most Volatile Stocks

Get a free copy of the Zacks research report on Design Therapeutics (DSGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Design Therapeutics (NASDAQ:DSGN)

Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.